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ABSTRACT A protein that imitates the sequence of a
highly conserved segment predicted to line the pore of dihy-
dropyridine-sensitive L-type calcium channels was designed
and synthesized. Single-channel conductance properties were
studied in planar lipid bilayers. The synthetic protein emulates
the ionic conductance, ionic selectivity, and pharmacological
properties of the authentic calcium channel, including the
stereospecific action of agonist and antagonist enantiomers of
the dihydropyridine BayK 8644. The identified sequence is
identical in L-type calcium channels from skeletal muscle and
isoforms ofcardiac muscle, brain, and aorta. It is plausible that
this structural motif represents the molecular blueprint for the
pore-forming structure of voltage-gated calcium channels.
Voltage-sensitive calcium channels play a key regulatory role
in cell biology as effectors of several signaling processes and
targets of a variety of drugs and toxins that alter the physi-
ology of the cell by modulating calcium flow (1, 2). Modu-
lators of the L-type calcium channels include the 1,4-
dihydropyridines (DHPs), which are of immense therapeutic
value (3).
The DHP-sensitive calcium channel from skeletal muscle is
composed of five subunits (4-7), a,, a2, f3, y, and 8, with the
a, subunit forming a functional voltage-gated calcium chan-
nel (8-10). Primary structures of the a, subunit of the DHP
receptor from skeletal (11) and cardiac (8) muscle, brain (12),
aorta (13), and lung (14) were elucidated. The amino acid
sequence of calcium- and sodium-channel proteins, which
show extensive homology, suggests the occurrence of four
homologous domains (I-IV) organized as pseudosubunits
around a central pore (11, 15, 16). Each repeat contains six
potential transmembrane segments (S1-S6).
A common function of S3 segments from calcium- and
sodium-channel proteins is suggested by the extensive amino
acid conservation, particularly with respect to negatively
charged or polar residues that may be involved in lining a
cation-selective channel. S3 segments contributed by each
homologous repeat may form an inner bundle of four a-hel-
ices, creating the transmembrane pore (15-17).
Here, we describe the chemical synthesis of such a four-
helix bundle (15-18): a 9-amino acid template molecule (19)
(Lys-Lys-Lys-Pro-Gly-Lys-Glu-Lys-Gly) was used to direct
the assembly of four identical 22-mer peptides (18) with
sequences representing the S3 segment of the fourth internal
repeat ofthe DHP-sensitive calcium channel (IVS3; Fig. lA).
The sequence of IVS3 is homologous in the other repeats and
is conserved between skeletal muscle (11) and isoforms of
cardiac muscle (8), brain (12), and aorta (13). Empirical
secondary structure predictors suggest that the peptide forms
an amphipathic a-helix (hydrophobic moment Au = 0.23) (20).
A homotetramer of IVS3 (T4CaIVS3) is, therefore, a plausi-
ble model ofthe proposed heterotetramer forming the pore of




were from Avanti Biochemicals (Alabaster, AL). Other re-
agents were of the highest purity available commercially.
Molecular Modeling. The model of T4CaIVS3 was gener-
ated by using existing coordinates for sodium-channel S3
homotetramer (22) by specific residue replacements. The
INSIGHT and DISCOVER program packages (Biosym Technol-
ogies, San Diego, CA) were used on a Silicon Graphics
(Mountain View, CA) 4D/210GTXB supercomputing work
station (S. Marrer and M.M., unpublished observations).
Synthesis and Purification of Proteins. Four-helix bundle
proteins were synthesized by solid-phase methods by simul-
taneously assembling the four identical peptide blocks after
cleavage ofthe E-amino groups oftemplate lysines (18). Resin
with substitution of 0.15 mmol/g was used (Applied Biosys-
tems). Coupling yields were .99.7% for each residue. Protein
was cleaved in HF and purified by reversed-phase HPLC.
Composition, sequence, and purity were confirmed by amino
acid analysis, microsequencing, HPLC, capillary zone elec-
trophoresis, and SDS/PAGE (apparent Mr, 9000).
Reconstitution in Lipid Bilayers. Bilayers were formed by
hydrophobic apposition of two monolayers at the tip of patch
pipettes and studied at 24 ± 20C (23). Monolayers were
spread from a suspension of hexane containing 1-palmitoyl-
2-oleoyl-sn-glycerophosphoethanolamine/1-palmitoyl-2-
oleoyl-sn-glycerophosphocholine (4:1; 5 mg/ml) and purified
protein at a molar ratio of 1000-10,000:1. Aqueous compart-
ments contained 50 mM divalent salt or 0.5 M monovalent
salt and 5 mM Hepes (pH 7.3). In experiments with mono-
valent cations as charge carriers, 1 mM BaCl2 was included.
T4CaIVS5 recordings were obtained in 50 mM BaCl2.
Data Acquisition and Analysis. Electrical recordings and
data processing were performed as described (17, 18). Rec-
ords were filtered at 1 or 0.5 kHz and digitized at 0.5 or 1 ms
per point for analysis and display, respectively, unless indi-
cated otherwise. Single-channel conductances (y) were cal-
culated from Gaussian fits to current histograms, and open
and closed lifetimes were determined from probability den-
sity analysis (17, 18); each value was calculated from record-
ings with .300 openings.
EXPERIMENTAL RESULTS AND DISCUSSION
A Bundle of Four Amphipathic a-Helices Is a Plausible
Structural Motif for the Calcium-Channel Pore. Low-energy
arrangements of a-helical bundles calculated with semiempir-
ical potential energy functions and optimization routines and
Abbreviations: y, single-channel conductance; DHP, dihydropyri-
dine.
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FIG. 1. Computer generated
molecular model of the synthetic
pore protein. (A) Amino acid se-
quences of template and oligopep-
tides used to generate the two pro-
teins studied, T4CaIVS3 and
T4CaIVS5. IVS3 and IVS5 corre-
spond to amino acids 1180-1201 and
1269-1291, respectively (11). Pep-
tides are attached to template ly-
sines, indicated with an asterisk. (B)
Stereo- side-view of energy opti-
mized parallel tetramer of IVS3 at-
tached to template (T4CaIVS3). The
}-hairpin structure at the top is the
template. Color code: green, ribbon
representation of the a-carbon
backbone; red, acidic; blue, basic;
yellow, polar, neutral; purple, lipo-
philic residues. The solvent acces-
sible surface (magenta, dotted) was
calculated with a probe radius of 1.4
A. The N terminus is at the bottom
of the structure and is assigned to
the intracellular face of the mem-
brane. (C) Stereo- end-view of
T4CaIVS3. The N terminus is in
front. The indole groups of Trp-3
form a square vestibule at the pore
entry with dimensions 4.5 x 4.5 A.
(D) Stereo- end-view of a cross-
section at the level of Asp-7 (red
dotted surface). A calcium ion is
confined within the pore. The dis-
tance between opposing carboxy-
lates is 4.2 A and is the narrowest
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FIG. 2. Single-channel currents from lipid bilayers containing the
synthetic T4CaIVS3 and T4CaIVS5 proteins in symmetric salt solu-
tions. Currents displayed were recorded at applied voltage V = 100
mV except CaCI2 (V = 120 mV) and barium 3,3-dimethylglutarate
(Baglu; V = 50 mV). Note that the channel open time in Baglu is
shorter than in BaC12. T4CaIVS5 recording was obtained in 50 mM
BaCl2. Current histograms generated from segments of records
lasting 45, 25, 50, 40, 25, 110, and 45 s, respectively (from top to
bottom). C, closed; 0, open.
further refined by molecular dynamics (22) are shown in Fig.
1 B-D. The side view (Fig. 1B) depicts the general structure of
the protein: the 9-amino acid template organized as a hairpin
with the four coupling sites at lysine side chains providing
spatial organization to the a-helical bundle. The orientation of
the free glutamic acid and lysine of the template is opposite
that of the four-helix bundle, which is funnel shaped with the
narrowest end pointing to the N terminus. The N-terminal
residue (Asp-1), which, in the model of the calcium-channel
protein, is assigned to the intracellular face of the membrane
(11), corresponds to the untethered end of the helices. The
Proc. Natl. Acad. Sci. USA 88 (1991)
helices are parallel and the bundle has a left-handed twist with
an interhelical angle of -15°. The length of the bundle is
sufficient to span the lipid bilayer (32 A) (22).
Fig. 1C displays a projection through the bundle, with the N
terminus in front. The solvent accessible surface is shown
(dotted) and dimensions are measured at the surface bound-
aries of the indicated groups. The exterior of the bundle is
hydrophobic and the lumen of the pore is lined with polar/
neutral residues and two clusters ofacidic residues (Asp-7 and
Asp-17). At the entry of the pore, a square vestibule with a
cross-section of 4.5 A is formed by tryptophan residues
(Trp-3). The shortest distance between the two antiparallel
strands of the template P hairin is =4 A. The pore diameter
at its narrowest extent is 4.2 and occurs at Asp-7.
Fig. 1D shows a transverse section across the bundle
depicting approximately one turn of helix bounded between
Phe-6 and Leu-9; a calcium ion is confined within the cavity.
The four carboxylates of Asp-7 create a ring of negative
charge surrounding the calcium ion.
Thus, the bundle offour amphipathic a-helices (T4CaIVS3)
satisfies the structural and energetic requirements for the
function of the inner bundle that forms the pore of calcium-
channel proteins: it exhibits fourfold symmetry and extensive
sequence homology, appropriate pore dimensions, and pore-
lining residues, which allow for cation selectivity, including
two sequential high-affinity calcium binding sites (Asp-7 and
Asp-17).
The Designed Pore Protein For Ion Channels in Lipid
Bilayers. Single-channel currents (I) at constant voltage (V)
recorded in symmetric salt solutions of the indicated ions are
shown in Fig. 2. The corresponding current histograms
illustrate the occurrence oftwo distinct states, closed (C) and
open (0). y, calculated from current histograms, is for
divalent ions (in 50 mM salt): Ca2', 7 pS; Ba2+, 10 pS; and
Sr2', 6 pS. y in BaCl2 and barium 3,3-dimethylglutarate is
equivalent, indicating the cation selectivity ofthe pore. In 0.5
M NaCl and KCl, y = 11 and 6 pS, respectively. The apparent
selectivity ratio inferred from conductance ratios is Ba2+ >
Ca2+ > Sr2+ > Na+ > K+ >> Cl-, in agreement with
measurements on authentic calcium channels (Table 1).
Sequence Specificity. To assess the specificity of the se-
quence selected for design of a calcium pore protein, we
identified a potential transmembrane segment, IVS5 (Fig.
LA), which is hydrophobic (,u = 0.07) and highly conserved,
yet is not considered to line an aqueous channel (15, 16, 20).
The peptide is predicted to be helical and the tetramer
T4CaIVS5 presumably forms a cluster ofa-helices. As shown
in Fig. 2 (lowest trace), the synthetic T4CaIVS5 does not form
distinct unitary conductance events characteristic ofchannel
proteins (n = 9), but only erratic and fluctuating drifts in
Table 1. Ionic conductance and modulator sensitivity of synthetic and authentic calcium channels
Conductance, pS Concentration,t M
Ion Synthetic Authentic Modulator Synthetic Authentic
Ca2+ 6.9 ± 0.3 (n = 9) 8 Nifedipine 10-7 (n = 6) 10-7 (25)
Ba2+ 10.2 ± 0.4 (n = 25) 25 Verapamil 10-6 (n = 5) 10-5 (25)
Sr2+ 6.4 ± 0.3 (n = 3) 9 QX-222 10-4 (n = 4) 10-4 (25)
Na+ 10.9 ± 0.7 (n = 5) NR Cd2+ 10-5 (n = 3) 10-5 (26, 27)
K+ 6.1 ± 0.3 (n = 4) NR Ca2+ 10-6 (n = 3) 10-6 (27)
(+)BayK 8644 10-7 (n = 4) 10-7 (28)
(-)BayK 8644 10-7 (n = 9) 10-7 (28)
Conductance values were calculated from Gaussian fits to current histograms. Values are means ± SEM; n denotes
number of experiments. Total number of events analyzed is 71,862. Values were obtained with synthetic calcium-channel
protein T4CaIVS3 compared with y reported for cardiac DHP-sensitive calcium channel (24). y for divalent (50 mM) or
monovalent (500 mM) ions was determined at 100 mV. NR, not reported under comparable conditions.
*y calculated from slopes of I-V plots in 50 mM chloride (pH 7.4).
tConcentration range at which channel activity is affected by the indicated modulator. Concentration required to increase
[(-)BayK 86441 or reduce (all other modulators) activity by -80%o for experiments with synthetic protein T4CaIVS3, or
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membrane current. The current histogram shows a single
broad band, in contrast to the two distinct peaks present in
recordings obtained with T4CaIVS3. Apparently, T4CaIVS5
is incorporated into the bilayer but does not form discrete
transmembrane structures. Thus, the single channels re-
corded with T4CaIVS3 indicate a requirement for sequence
specificity in the design.
Ionic Selectivity and Conduction Through the Synthetic Pore
Protein. To establish the selectivity of the protein between
cations and anions, I-V relations (-100 mV . V < 100 mV)
in different salt solutions under symmetric conditions and
under single salt concentration gradients were measured. The
channel is ohmic in both conditions. Transference numbers
for Ca2+ (0.91 + 0.07; n = 4) and Ba2+ (0.95 + 0.08; n = 3),
calculated from reversal potentials obtained under 10-fold
concentration gradients of CaC12 or BaCl2, indicate that the
current-carrying species is the cation.
fy increases with salt concentration and approaches satu-
ration. The apparent salt concentration at which y is half-
maximal is 21 mM for Ba2+, 18 mM for Ca2+, and 14 mM for
Sr2+, in fair agreement with values of authentic calcium
channels (24). Thus, the synthetic channel protein forms
cation-selective pores that exhibit saturation consistent with
the occurrence of low-affinity (mM) binding sites for divalent
cations within the pore lumen.
Pharmacological Specificity. Calcium channels are recep-
tors for a variety of drugs, including many DHP derivatives
(e.g., nifedipine) and other channel blockers (e.g., verapamil
and local anesthetics), which are of clinical importance. The
significance of DHP compounds is underscored by the avail-
ability of enantiomers that act as activators (agonists) or
blockers (antagonists) of calcium channels (29). This phar-
macological specificity provides a valuable tool to assess the
integrity of the designed pore protein.
As shown in Fig. 3, nifedipine, verapamil, and QX-222, a
quaternary ammonium derivative of the local anesthetic
lidocaine, block ion conduction through the synthetic pore
protein. Fig. 3 shows segments of single-channel recordings
obtained before (traces A) and after (traces B and C) addition
of blocker; recordings obtained in the presence of modulator
are selected to qualitatively display channel activity. Blocking
is initially manifested as increased occurrence of brief open-
ings or fast interruptions (flickering) of the long-lived open
state, whereas y is unaltered. This is evident in trace B from
each group of recordings. The pattern of channel activity is
progressively dominated by the infrequent occurrence of very
brief events. Eventually the open-channel lifetime cannot be
resolved, leading to an apparent reduction of y (trace C). As
summarized in Table 1, blocking is effective at similar con-
centrations in both synthetic and authentic calcium channels.
The Synthetic Calcium Channel Is Blocked by Cd21 and Ca2+.
A key property of calcium channels is their susceptibility to
block by polyvalent metal ions such as Cd2+; divalent ion
currents through synthetic channels are also blocked by micro-
molar Cd2+ (Fig. 3). Ca2+ blocks monovalent currents through
authentic calcium channels; as shown in Fig. 3, Ca2+ blocks K+
currents through the synthetic pore protein. Long openings
dominate before addition of Ca2', which immediately results in
the occurrence of brief openings and a shortening of the long
open time. Accordingly, the designed protein contains intrapore
Ca2+ binding sites of high affinity (,uM; Table 1), in accordance
with authentic calcium channels (1, 26, 27).
The Activity of DHP on the Synthetic Pore Protein Is
Stereospecific. Antagonist and agonist effects of DHP enan-
tiomers are displayed in Fig. 4. After addition of (+)BayK
8644 (antagonist), a drastic reduction in the number of
openings and in the open lifetime is evident. Conversely, the
agonist effect of the (-)-enantiomer ofBayK 8644 is indicated
by an increased open probability and a prolongation of
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FIG. 3. Blocking of ion conduction through the synthetic calcium
channel. Single-channel currents were from lipid bilayers containing
T4CaIVS3 in symmetric 50mM BaCJ2 (first four groups of recordings)
or symmetric 0.5 M KCI (last group of recordings). Current traces are
before (traces A) and after(traces B andC) addition of blocker. Currents
were recorded at V = 100 mV except for nifedipine (V = 50 mV).
Nifedipine: trace A, control; traces B and C, recorded 1 and 2 min after
addition of 100 nM nifedipine; open channel probability (Po) reduced
from 60o to <2%. Verapamil: trace A, control; traces B and C,
recorded1 min after addition of 2.4 and 4.8AM verapamil, a reduction
of Po from 65% to <2%. QX-222, trace A, control; traces B and C,
recorded 1and 5 min after addition of 250 AM QX-222; Po was reduced
from 50% to -5%.Cd2+: trace A, control; traces B and C, 1 and 3 min
after addition of 10 AM CdCl2. Po was reduced from 40o to <2%.
Records were filtered at 400 Hz for display. Ca2+: trace A, control, in
0.5 M KCI; traces B and C, consecutive records 3 min after addition of
1 mM CaC12; Po was reduced from 74% to -<5% after 10 min. Stock
solutions (10mM in ethanol) of nifedipine were stored refrigerated in the
dark. Other conditions are as described (23). C, closed; 0, open.
on the synthetic channel matches that exerted on authentic
channels (for review, see refs. 1 and 2).
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FIG. 4. Stereoselective modulation of the synthetic calcium
channel by antagonist and agonist DHP derivatives. Single-channel
currents from lipid bilayers containing T4CaIVS3 in symmetric 50
mM BaCl2 before (Control; V = 100 mV) and after addition of drug.
Recordings in the presence of (+)BayK 8644 [200 nM; open channel
probability (Po) < 2%; V = 50 mV; filtered at 300 Hz] and (-)BayK
8644 (100 nM; Po a 50%6; V = 100 mV) start 1 and 5 min after addition
of compound, respectively. The display is interrupted (90 s) to show
the persistence of the drug effect. Other conditions are as described
(23).
A Plausible Unifying Structural Motif for the Pore of Cation-
Selective Channels. A search for sequences compatible with
a three-dimensional structure used as pathway for Ca2W led
to the identification of IVS3. The designed bundle of four
identical a-helices representing IVS3 features a narrowest
cross-section of 4.2 A, which agrees with the geometric
constraints of the DHP-sensitive calcium channel (1, 2). The
finding that affinity for Ca2+ measured by block (55 AuM) and
by saturation (18 mM) are different indicates that at least two
Ca2l binding sites are associated with the synthetic pore
protein, a biophysical hallmark ofthe authentic protein (1, 2).
The pharmacological specificity exhibited by the synthetic
channel demonstrates that the design mimics the inner bundle
that lines the calcium channel.
The extensive sequence homology between calcium and
sodium channels at the level of S3 supports the notion that a
bundle of four S3 a-helices may represent a unifying struc-
tural motif for the inner bundle of this superfamily of voltage-
gated, cation-selective channels (15-17, 22). The "selectivity
filter," a key property of cation-selective channels (2), may
correspond to the ring of conserved aspartic acid residues
exposed to the luminal face of the pore (Fig. 1D). The
proposal that such a structural motif represents a molecular
blueprint for the pore structure of this superfamily of channel
proteins is further substantiated by the comparable sensitiv-
ity of authentic sodium and calcium channels and of the
synthetic pore protein to drugs, such as local anesthetics (30,
31), and the stereoselective action ofBayK 8644 enantiomers
(32, 33). Potential binding sites for verapamil (34) and nitren-
dipine (35) were assigned to a sequence succeeding the 1V56
repeat in the predicted cytoplasmic domain of the calcium-
channel protein. The availability of the structure model (Fig.
1) and of the synthetic pore protein should prove valuable in
assessing the functional role of key residues and should
facilitate the conceptual design ofdrugs that alter the pore by
blocking it from the aqueous pathway or via the hydrophobic
access to the protein from the bilayer interior.
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